Abstract
In the last few years, DNA methylation has become one of the most studied gene regulation mechanisms in carcinogenesis as a result of the cumulative evidence produced by the scientific community. Moreover, advances in the technologies that allow detection of DNA methylation in a variety of analytes have opened the possibility of developing methylation-based tests. A number of studies have provided evidence that specific methylation changes can alter the response to different therapeutic agents in cancer and, therefore, be useful biomarkers. For example, the association of the methylation status of DNA repair genes such as MGMT and MLH1 illustrate the two main mechanisms of response to DNA damaging agents. Loss of methylation of MGMT, and the subsequent increase in gene expression, leads to a reduction in response to alkylating agents as a result of enhanced repair of drug-induced DNA damage. Conversely, the increase in methylation of MLH1 and its resulting loss of expression has been consistently observed in drug-resistant tumor cells. MLH1 encodes a mismatch repair enzyme activated in response to DNA damage; activation of MLH1 also induces apoptosis of tumor cells, and thus loss of its expression leads to resistance to DNA-damaging agents. Other methylation-regulated genes that could serve as biomarkers in cancer therapy include drug transporters, genes involved in microtubule formation and stability, and genes related to hormonal therapy response. These methylation markers have potential applications for disease prognosis, treatment response prediction, and the development of novel treatment strategies.
Similar content being viewed by others
References
Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000 Nov 9; 343(19): 1350–4
Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004 Aug 1; 10(15): 4933–8
Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004 Mar 15; 10(6): 1871–4
Balana C, Ramirez JL, Taron M, et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis (2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003 Apr; 9(4): 1461–8
Esteller M, Gaidano G, Goodman SN, et al. Hypermethylation of the DNA repair gene O (6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 2002 Jan 2; 94(1): 26–32
Christmann M, Pick M, Lage H, et al. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 2001 Apr 1; 92(1): 123–9
Balch C, Huang TH, Brown R, et al. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 2004 Nov; 191(5): 1552–72
Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the MLH1 gene promoter. Cancer Res 2000 Nov 1; 60(21): 6039–44
Arnold CN, Goel A, Boland CR. Role of MLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003 Aug 10; 106(1): 66–73
Worm J, Kirkin AF, Dzhandzhugazyan KN, et al. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem 2001 Oct 26; 276(43): 39990–40000
Hsueh CT, Dolnick BJ. Regulation of folate-binding protein gene expression by DNA methylation in methotrexate-resistant KB cells. Biochem Pharmacol 1994 Mar 15; 47(6): 1019–27
Efferth T, Futscher BW, Osieka R. 5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs. Blood Cells Mol Dis 2001 May–Jun; 27(3): 637–48
Kantharidis P, El-Osta S, Silva M, et al. Regulation of MDR1 gene expression: emerging concepts. Drug Resist Updat 2000 Apr; 3(2): 99–108
Baker EK, El-Osta A. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 2003 Nov 1; 290(2): 177–94
Bearzatto A, Szadkowski M, Macpherson P, et al. Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res 2000 Jun 15; 60(12): 3262–70
Christmann M, Kaina B. Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents. J Biol Chem 2000 Nov 17; 275(46): 36256–62
Roman-Gomez J, Castillejo JA, Jimenez A, et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J Clin Oncol 2003 Apr 15; 21(8): 1472–9
Duan Z, Feller AJ, Toh HC, et al. TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 1999 Mar 18; 229(1–2): 75–81
Duan Z, Duan Y, Lamendola DE, et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 2003 Jul; 9(7): 2778–85
Yao X, Hu JF, Li T, et al. Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors. Cancer Genet Cytogenet 2004 May; 151(1): 1–13
Satoh A, Toyota M, Itoh F, et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003 Dec 15; 63(24): 8606–13
D’Andrea AD. The Fanconi anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2003 Jul-Aug; 2(4): 290–2
Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003 May; 3(5): 417–20
Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003 May; 9(5): 568–74
Liu L, Tommasi S, Lee DH, et al. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 2003 Nov 6; 22(50): 8125–36
Koul S, McKiernan JM, Narayan G, et al. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer 2004 May 18; 3(1): 16
Lafarge S, Sylvain V, Ferrara M, et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001 Oct 4; 20(45): 6597–606
Widschwendter M, Berger J, Muller HM, et al. Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J Mammary Gland Biol Neoplasia 2001 Apr; 6(2): 193–201
Virmani AK, Rathi A, Zöchbauer-Müller S, et al. Promoter methylation and silencing of the retinoic acid receptor beta in lung carcinomas. J Natl Cancer Inst 2000 Aug; 92(16): 1303–7
Esteller M, Guo M, Moreno V, et al. Hypermethylation-associated Inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res 2002 Oct 15; 62(20): 5902–5
Chang HG, Kim SJ, Chung KW, et al. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene. J Mol Med 2005 Feb; 83(2): 132–9
Yang X, Phillips DL, Ferguson AT, et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001 Oct 1; 61(19): 7025–9
Jarrard DF, Kinoshita H, Shi Y, et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 1998 Dec 1; 58(23): 5310–4
Izbicka E, MacDonald JR, Davidson K, et al. 5,6 Dihydro-5′-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells. Anticancer Res 1999 Mar–Apr; 19(2A): 1285–91
Bird A. The essentials of DNA methylation. Cell 1992 Jul 10; 70(1): 5–8
Cross S, Bird A. CpG islands and genes. Curr Opin Genet Dev 1995; 5: 309–14
Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U S A 1993 Dec 15; 90(24): 11995–9
Chan MF, Liang G, Jones PA. Relationship between transcription and DNA methylation. Curr Top Microbiol Immunol 2000; 249: 75–86
Hermann R, Doerfler W. Interference with protein binding at AP2 sites by sequence-specific methylation in the late E2A promoter of adenovirus type 2 DNA. FEBS Lett 1991 Apr 9; 281(1–2): 191–5
Clark SJ, Harrison J, Molloy PL. Sp1 binding is inhibited by (m)Cp (m)CpG methylation. Gene 1997 Aug 11; 195(1): 67–71
Prendergast GC, Ziff EB. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 1991 Jan 11; 251(4990): 186–9
Bester TH. Gene silencing: methylation meets acetylation. Nature 1998 May 28; 393(6683): 311–2
Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997 Feb 21; 88(4): 471–81
Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998 May 28; 393(6683): 386–9
Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998 Jun; 19(2): 187–91
Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002 Apr; 1(4): 287–99
Marks PA, Richon VM, Breslow R, et al. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001 Nov; 13(6): 477–83
Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003 Jan; 3(1): 89–95
Chan MF, Liang G, Jones PA. Relationship between transcription and DNA methylation. Curr Top Microbiol Immunol 2000; 249: 75–86
Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001 May 28; 20(24): 3139–55
Pradhan S, Bacolla A, Wells RD, et al. Recombinant human DNA (cytosine-5) methyltransferase: I. expression, purification, and comparison of de novo and maintenance methylation. J Biol Chem 1999 Nov 12; 274(46): 33002–10
Chuang LS, Ian HI, Koh TW, et al. Human DNA- (cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 1997 Sep 26; 277(5334): 1996–2000
Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69: 915–26
Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature 1993; 366: 362–5
Panning B, Jaenisch R. RNA and the epigenetic regulation of X chromosome inactivation. Cell 1998; 93: 305–8
Walsh CP, Chaillet JR, Bestor TH. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat Genet 1998; 20: 116–7
Richardson B. Impact of aging on DNA methylation. Ageing Res Rev 2003 Jul; 2(3): 245–61
Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004 May 27; 429(6990): 457–63
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002 Jun; 3(6): 415–28
Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003 Apr; 3(4): 253–66
Ludlum DB. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res 1990 Nov–Dec; 233(1–2): 117–26
Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998 Oct; 16(10): 3310–5
Chen ZP, Yarosh D, Garcia Y, et al. Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Can J Neurol Sci 1999 May; 26(2): 104–9
Aquilina G, Hess P, Branch P, et al. A mismatch recognition defect in colon carcinoma confers DNA microsatellite instability and a mutator phenotype. Proc Natl Acad Sci U S A 1994 Sep 13; 91(19): 8905–9
Karran P, Bignami M. DNA damage tolerance, mismatch repair and genome instability. Bioessays 1994 Nov; 16(11): 833–9
Brown R, Hirst GL, Gallagher WM, et al. MLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997 Jul 3; 15(1): 45–52
Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003 Jul; 3(7): 502–16
Kat A, Thilly WG, Fang WH, et al. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A 1993 Jul 15; 90(14): 6424–8
Gifford G, Paul J, Vasey PA, et al. The acquisition of MLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004 Jul 1; 10(13): 4420–6
Johnson L, Chu E. Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instability. Clin Colorectal Cancer 2002 Nov; 2(3): 146–8
Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003 Jul; 4(4): 397–410
Kantharidis P, El-Osta A, deSilva M, et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 1997 Nov; 3(11): 2025–32
Rothem L, Stark M, Kaufman Y, et al. Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. J Biol Chem 2004 Jan 2; 279(1): 374–84
Ferreri AJ, Dell’Oro S, Capello D, et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol 2004 Sep; 126(5): 657–64
Toyota M, Sasaki Y, Satoh A, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci U S A 2003 Jun 24; 100(13): 7818–23
Li LC, Chui R, Nakajima K, et al. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res 2000 Feb 1; 60(3): 702–6
Zhao C, Lam EW, Sunters A, et al. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003 Oct 23; 22(48): 7600–6
Lapidus RG, Ferguson AT, Ottaviano YL, et al. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996 May; 2(5): 805–10
Nass SJ, Herman JG, Gabrielson E, et al. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000 Aug 15; 60(16): 4346–8
Sasaki M, Kaneuchi M, Fujimoto S, et al. Hypermethylation can selectively silence multiple promoters of steroid receptors in cancers. Mol Cell Endocrinol 2003 Apr 28; 202(1–2): 201–7
Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004 Jun 1; 64(11): 3807–13
Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000 Apr 15; 28(8): e32
Maier S, Nimmrich I, Marx A, et al. DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients [abstract for oral presentation]. In: Grunberg SM, editor. 40th Annual Meeting of the American Society of Clinical Oncology: Annual Meeting Proceedings; 2004 Jun 5–8; New Orleans. 525
Toyota M, Kopecky KJ, Toyota MO, et al. Methylation profiling in acute myeloid leukemia. Blood 2001 May 1; 97(9): 2823–9
Dowell JE, Minna JD. Cancer chemotherapy targeted at reactivating the expression of epigenetically inactivated genes. J Clin Oncol 2004 Apr 15; 22(8): 1353–5
Reid GK, Besterman JM, MacLeod AR. Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment. Curr Opin Mol Ther 2002 Apr; 4(2): 130–7
Acknowledgments
All authors are the employees of Epigenomics, a company developing DNA-methylation based biomarkers.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maier, S., Dahlstroem, C., Haefliger, C. et al. Identifying DNA Methylation Biomarkers of Cancer Drug Response. Am J Pharmacogenomics 5, 223–232 (2005). https://doi.org/10.2165/00129785-200505040-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00129785-200505040-00003